Mr. Vito Sanzone reports

RESEARCH TO EXPLORE PROMINO'S PATENTED AMINO ACID BLEND IN ADDRESSING TREATMENT-RELATED MUSCLE WASTING IN TWO OF THE MOST PREVALENT CANCERS AMONG WOMEN AND MENSTUDY LED BY DR. PATRICK GUNNING, PROFESSOR OF MEDICINAL CHEMISTRY AND MOLECULAR THERAPEUTICS, UNIVERSITY OF TORONTO AND UNIVERSITY OF GLASGOW

Promino Nutritional Sciences Inc. has launched its second round of preclinical studies evaluating the effects of Promino, a patented essential amino acid (EAA) blend, on muscle preservation and systemic health during chemotherapy treatment for breast and prostate cancer -- the most commonly diagnosed cancers in women and men, respectively.

The preclinical trials will be conducted using murine models and aim to provide critical insights into the role of Promino's clinically formulated EAA blend in counteracting the severe muscle loss (cachexia) often associated with chemotherapy. The studies are being led by Dr. Patrick Gunning, a globally recognized medicinal chemist and chief scientific adviser to Promino.

Addressing a widespread and underserved need in oncology support

Breast cancer affects more than 2.3 million women globally each year, while prostate cancer impacts over 1.4 million men annually. Despite advances in oncology, many patients suffer significant declines in muscle mass and function during chemotherapy, impairing both treatment tolerance and recovery outcomes.

"These preclinical studies represent a critical step toward understanding how targeted amino acid formulations can support patients undergoing highly demanding chemotherapy protocols," said Dr. Gunning, chief scientific adviser to Promino. "Preserving muscle mass and function is not only about quality of life, it may also influence treatment outcomes and recovery trajectories. We're excited to be advancing this vital research."

Rooted in breakthrough science by leading researchers

Promino's formulation was developed by Dr. Robert Wolfe of the University of Arkansas, leaders in amino acid science and pioneers in the study of muscle metabolism. Their patented EAA blend is optimized to stimulate muscle protein synthesis, even in the face of metabolic stress such as surgical recovery and extreme metabolic deficit.

Toward a dedicated oncology line for patients and providers

This latest preclinical initiative will not only help inform Promino's future clinical roadmap but also support the development of a Promino line specifically tailored to oncology care with the goal of providing patients, health-care systems and medical professionals with targeted nutritional tools to help combat treatment-related muscle wasting.

"This is a landmark moment for Promino and the science behind our proprietary amino acid blend," said Vito Sanzone, chief executive officer of Promino. "We are uniquely positioned to lead the intersection of clinical nutrition and cancer care. Our goal is to deliver Promino as a precision nutritional therapy that supports better treatment tolerance, faster recovery and stronger quality of life."

Next steps

The new preclinical studies follow encouraging initial data and are designed to meet rigorous scientific standards. Results will inform future human trials and potential clinical collaborations with leading oncology institutions in North America.

About Promino Nutritional Sciences Inc.

Promino is an innovative and research-driven Canadian nutraceutical company specializing in the development of patented and science-based products for the global consumer packaged goods market, with a portfolio focused specifically on muscle health. Promino's lead product, Rejuvenate Muscle Activator, is a patented proprietary formulation that is clinically proven to assist in the building, rebuilding, restoration and rejuvenation of natural muscle mass. Promino also offers Promino, an elite performance supplement for both professional and amateur athletes to accelerate muscle recovery, build strength and accelerate recovery from injury. Promino was founded in 2015 and is located in Burlington, Ont.

We seek Safe Harbor.